Hepatocellular carcinoma is one of the most common cancers worldwide. Despite several efforts to elucidate hepatocellular carcinoma molecular pathogenesis, it is still not fully understood. To acquire further insights into the molecular mechanisms of hepatocellular carcinoma, we performed a systematic functional genomic approach on human HuH-7 and JHH-6 cells. The subsequent analysis of the differentially expressed genes in human specimens revealed a molecular signature of 11 genes from which we selected the LGALS1 gene, which was overexpressed in hepatocellular carcinoma. The expression analysis in humans of Galectin-1 (Gal-1), the protein encoded by LGALS1, showed a Gal-1 preferential accumulation in the stromal tissue around hepatocellular carcinoma tumors. Moreover, a significant association between increased expression of Gal-1 in hepatocellular carcinoma and the presence of metastasis was observed. Interestingly, Gal-1 overexpression resulted in an increase of cell migration and invasion. In conclusion, this study provides a portfolio of targets useful for future investigations into molecular marker-discovery studies on a large number of patients and functional assays. In addition, our data provide evidence that Gal-1 plays a role in hepatocellular carcinoma cell migration and invasion, and we suggest that further studies should be conducted to fully establish the role of Gal-1 in hepatocellular carcinoma pathogenesis and evaluate Gal-1 as a potential molecular therapeutic target.
INTRODUCTION
Hepatocellular carcinoma (HCC) is the fifth most common malignancy worldwide and is the third most common cause of cancer-related death. Globally, the 5-year survival rate of HCC is <5%, and approximately 598,000 HCC patients die each year (1) . Although surgery remains the only and the most effective therapeutic approach for HCC, most HCC patients are still ineligible for surgical intervention (2) . For those who qualify for surgery, the subsequent improvement in long-term survival is only modest, owing to a high rate of recurrence or intrahepatic metastases that develop through invasion of the portal vein or spread to other parts of the liver (3, 4) . To improve prognosis and treatment of HCC, information regarding the phenotypic and molecular changes associated with the development of this disease must be determined. Despite several previous efforts, our current understanding of HCC is still rather limited (5) .
Gene expression profiling is a useful approach to elucidate the molecular events underlying HCC development and to identify novel diagnostic markers as well as therapeutic and preventive targets. However, the selection of potentially important candidate genes for further studies (which are derived from lengthy gene lists generated from gene expression profiling studies) is challenging for several reasons, including the presence of many confounding factors in the gene expression profile data from human cancer tissues (differences in age, hospital care and treatment protocols; nonparallel progression of cancer; and environment factors). For this reason, to acquire further insight into the molecular mechanisms of HCC, we performed a systematic functional genomic approach to investigate human HuH-7 and JHH-6 HCC cells. The former are considered an acceptable model for differentiated HCC, whereas the latter are models for undifferentiated, more malignant liver cancer (6) (7) (8) (9) (10) . With this approach and the subsequent gene expression analysis on human HCC specimens, we identified an HCC molecular signature consisting of 11 genes that may play important roles in hepatocarcinogenesis. Among these genes, we focused our attention on LGALS1, which was overexpressed in human HCC.
LGALS1 encodes the Galectin-1 (Gal-1) protein, which belongs to a family of soluble lactose-binding lectins (galectins) characterized by their affinity for β-galactoside moieties. Gal-1 is a multifunctional protein involved in various aspects of tumorigenesis (cell-extracellular matrix and cell-cell interactions, cell migration, angiogenesis, tumor-immune escape) and has been described as a promising cancer target (11) (12) (13) . Gal-1 expression has been examined in several malignant tumors (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) , and its correlation with tumor invasiveness and lymph node metastasis was demonstrated in breast cancer (25) , neuroblastoma (26) , oral squamous cell carcinoma and lung adenocarcinoma (27) . Although Kondoh et al. (28) showed that the activation of LGALS1 gene expression in HCC results from promoter hypomethylation, data on Gal-1 protein expression in HCC and its correlation to clinicopathological parameters were not available. The role of Gal-1 in molecular mechanisms leading to cancer development has been analyzed in several tumors (11) but surprisingly never in the molecular pathogenesis of HCC. In particular, it is still unknown whether Gal-1 affects the invasive ability of HCC as previously shown in other malignant tumors (25) (26) (27) .
In this study, we performed a comprehensive Gal-1 protein expression analysis in resection specimens of patients with HCC, nontumorous liver tissues and normal liver tissues by using a clinically well-characterized tissue microarray (TMA) and correlated our findings with patient clinicopathological parameters. Moreover, we provide direct functional evidence demonstrating that Gal-1 affects the ability of tumor invasion in HCC cell lines.
MATERIAL AND METHODS

Cell Culturing
HuH-7 (differentiated human hepatoma) and JHH-6 cells (undifferentiated hepatocellular carcinoma) were obtained from Japan Health Science Research Resources Bank (Rinku Town, Osaka, Japan) and grown according to the manufacturer's protocol.
Microarray Analysis
RNA isolation from cell lines, gene profiling, microarray data processing and statistical analysis, as well as gene ontology analysis are described in detail in the online supplementary material. Briefly, we performed a microarray experiment in triplicate on JHH-6 and HuH-7 total RNA using U133Plus 2.0 GeneChip Human Genome (Affymetrix UK, High Wycombe, UK). The raw gene expression data (.CEL files) are provided as supplementary material. The quality control and the expression measures of each chip were performed using the affy package from the R Computing Environment (http://www.bioconductor.org/). The expression measures were performed using robust multiarray average (29) . Gene expression analysis was performed by Cyber-T (http://visitor.ics.uci. edu/genex/cybert/). Significance levels were adjusted according to the Bonferroni method. Differentially expressed genes were classified according to the DAVID 2008 functional annotation system (http://david.abcc.ncifcrf.gov).
Real-Time Quantitative Polymerase Chain Reaction
Real-time quantitative polymerase chain reaction (QRT-PCR) experiments and statistical analysis are described in detail in the supplementary material. Briefly, we used TRIZOL reagent (Invitrogen, Milano, Italy) to isolate total RNA from cells, human HCC, cirrhosis surrounding HCC (SLC) and cirrhosis distal from HCC (DLC) specimens. cDNA was synthesized by random hexamers with the SuperScript First-Strand Synthesis System for RT-PCR kit (Invitrogen). QRT-PCR was performed as previously described (30) . GAPDH, rRNA 18S and β-actin mRNAs were used to normalize mRNA concentration. The statistical analysis was performed as previously described (30, 31) .
Patients
Twenty patients, followed at the Centro Studi Fegato (Trieste), who prospectively underwent surgical treatment of HCC, were included in the study. HCC, SLC and DLC specimens from each patient were collected at the time of surgery and snap frozen. HCC diagnosis was established based on international criteria for HCC diagnosis and treatment (32) and confirmed by histological analysis. HCC specimens were histologically classified according to the Edmondson and Steiner criteria (33) . Patient clinical findings are summarized in Table 1 . No patient had undergone chemotherapy before surgery.
TMA Construction and Immunohistochemistry
The files of the Institute of Pathology, University Hospital Basel, and the De- Tables 2, 3 and 4. The male to female ratio was 3.4:1, mean age at diagnosis was 69.9 years (range 10-93 years). For TMA construction, the number of punches per tissue type and patient ranged from 1 to 3. One punch was collected per patient on average (median 1.0) for each of the tissue types. We performed immunohistochemical analysis as previously described (34) using a mouse monoclonal anti-galectin-1 antibody (1:250; Novocastra, Newcastle upon Tyne, UK) detected by an antimouse peroxidase-conjugated EnVision antibody (Dako, Baar, Switzerland). Sections were counterstained with hematoxylin. Negative control consisted of primary antibody omission.
Gal-1 immunoreactivity was analyzed independently by two pathologists and was scored semiquantitatively by evaluating the number of positive hepatocytes and stroma cells over the total number of hepatocytes and stroma cells, respectively. Scores were assigned by use of 10% intervals and ranged from 0% to 100%. The staining intensity was semiquantitatively recorded as 0, 1, 2 or 3. A total of 197 HCC samples were divided into two groups based on the staining intensity: 0 and 1 (n = 153) versus 3 and 4 (n = 44). The absolute frequencies were compared by use of the Pearson chi-square test. Quantitative clinical data were compared by use of the Mann-Whitney test. P ≤ 0.05 was considered significant.
Immunoblotting
Total protein extracts were prepared and used for immunoblotting as previously described (35) by use of goat anti-galectin-1 (0.2 μg/mL; R&D Systems, Minneapolis, MN, USA), rabbit anti-Syk (1:1000; Cell Signaling Technology, Danvers, MA, USA) and rabbit anti-phospho-Zap-70 (Tyr319)/Syk (Tyr352) antibodies (1:1000; Cell Signaling Technology) detected by horseradish peroxidase-conjugated antigoat and antirabbit antibodies (1:5000) (Santa Cruz Biotechnology, Santa Cruz, CA, USA). A mouse anti-β-actin antibody (1:5.000; Sigma-Aldrich, Milan, Italy) was used as a control for equal loading.
Construct Preparation
We isolated total RNA from JHH-6 cells using TRIZOL reagent (Invitrogen). cDNA was synthesized by oligo(dT) with a SuperScript First-Strand Synthesis System for RT-PCR kit (Invitrogen). The LGALS1 cDNA was amplified by specific primers for LGALS1 (5′-GAGTCTTCTG ACAGCTGGTGC-3′ and 5′-TGATT TCAGT CAAAGGCCACAC-3′) with Pfu DNA Polymerase (Promega, Milan, Italy) and cloned to the plasmid pBluescript EcoRV. After sequencing, the 500-bp BamHI-XhoI fragment of LGALS1 cDNA was cloned to the plasmid pcDNA3.1 BamHI-XhoI (pcDNA3.1-LGALS1 plasmid). 
Cell Transfection
One d before transfection, HuH-7 cells were plated in a 100-mm dish. At the time of transfection, the cell confluence was 70%, and the cells were transiently transfected with 6 μg pcDNA3.1-LGALS1 plasmid or the empty vector using TransIT-LT1 transfection reagent (Mirus, Madison, WI, USA). Forty-eight h after transfection, the cells were briefly cultured for 72 h under the selection pressure of 3 mg/mL G418 (Gibco, Milan, Italy) to kill the untransfected cells. After 72 h, the cells were harvested; the LGALS1 and Gal-1 expression levels were evaluated and cell invasion and migration assays were performed.
Cell Invasion and Migration Assays
We determined cell invasiveness by using chamber inserts (24-well format, polycarbonate membrane filter of 8-μm pore size) (Corning, Milan, Italy), which were coated with 10 μg matrigel (Matrigel Basement Membrane Matrix, BD Biosciences, Buccinasco, Italy). A total of 25,000 cells, transfected with pcDNA3.1-LGALS1 plasmid or the empty vector, were seeded onto the upper chamber in DMEM medium without FBS. DMEM medium in the lower chamber contained 5% FBS served as a chemoattractant. After 2 h, cells migrating to the lower membrane surface were fixed and stained with hematoxylin/eosin. Cells were photographed and counted in six random fields per membrane at 10× magnification using a light microscope. The experiments were carried out in duplicate, and two independent sets of experiments were carried out. The migration assay was carried out as described in the invasion assay in the absence of matrigel.
All supplementary materials are available online at www.molmed.org.
RESULTS
Gene Expression Profile in HCC Cells
The gene expression profile of JHH-6 cells compared with HuH-7 cells showed 47 (27 upregulated and 20 downregulated) significantly differentially expressed genes (Table 5) . Two upregulated genes (C8orf47 and LOC344887) were unknown. The genes belong to different functional groups ( Figure 1A) ; 11 of 20 downregulated genes (55%) are known to be involved in metabolic pathways, and in particular TF, APOA II, FABP1 and APOA I liver-specific genes were the most strongly downregulated. Conversely, the upregulated genes are known to be involved in several biological processes, and in particular in cell proliferation/ differentiation/apoptosis (AKT3, IFI16, LGALS1, TRIM16), transcription regulation (ZIC2, PITX1, TRIM16), angiogenesis (EDIL3), cell-cell and cell-substrate interaction (LGALS1), and cell movement (LGALS1, MSN, Cdc42ep3) . Several genes map to allelic imbalance chromosomal regions involved in HCC (Table 5) . Interestingly, genes involved in cell proliferation (IFI16) and in transcription regulation (ZIC2, PITX1, TRIM16) mapped to allelic imbalance chromosomal regions involved in HCC. Moreover, previous data demonstrated that DLK1, GSTP1, MAGEA3 and LGALS1 gene expression in HCC is regulated by methylation status changes of the promoter (Table 5 ). The significant differential expression of these genes was validated by QRT-PCR using GAPDH and β-actin as housekeeping genes ( Figure 1B, C) .
Gene Expression Profile in Human HCC Specimens
We analyzed the expression profile of differentially expressed genes in 20 human HCC, SLC and DLC specimens by QRT-PCR using β-actin ( Figure 2 ) and rRNA 18S (Supplementary Figure 1) A with both β-actin ( Figure 2B ) and rRNA 18S (Supplementary Figure 1B) . We confirmed the previously reported upregulation of EDIL3 (36), LGALS1 (28) and SERPINI1 (37) genes and observed the upregulation of AKR1C3, C8orf47, COLIVA2, MSN, OGFRL1, PSCD3, TRIM16 and ZIC2 genes. The upregulation of SERPINI1, C8orf47, COLIVA2 and ZIC2 genes is in agreement with their location on chromosomal regions gained in HCC. Moreover, the TRIM16 gene maps to an allelic imbalance chromosomal region involved in HCC (Table 5) . We performed a gene ontology analysis on the 11 identified genes. As shown in Table 6 , the most representative classes were GO:0007275 and GO:0048856. Both terms are present in LGALS1 annotation. The remaining genes did not show a significant differential expression profile with both β-actin and rRNA 18S (data not shown).
Gal-1 Expression in Human Specimens
We analyzed the Gal-1 expression profile in human normal liver, cirrhotic tissue and HCC specimens by immunohistochemical analysis on TMA. Gal-1 was detected both in hepatocytes (hepatocyte expression) and stroma cells (stromal expression) in all three types of specimens ( Figure 3A) . Gal-1 hepatocyte expression was significantly higher in normal liver specimens than cirrhotic and HCC specimens (P < 0.001). The opposite trend was observed for Gal-1 stromal expression, with expression significantly lower in normal liver specimens than cirrhotic and HCC specimens (P = 0.006) ( Figure 3B) . We compared Gal-1 hepatocyte or stromal expression of normal liver versus cirrhotic specimens, and of cirrhotic versus HCC specimens. A significant differential expression was found between normal liver and cirrhotic specimens relative to Gal-1 hepatocyte expression (P < 0.001; Mann-Whitney test).
A significant association was found between increased expression of Gal-1 in HCC and the presence of metastasis (odds ratio = 2.33; 95% confidence interval, 1.00-5.40; P = 0.04). No significant associations were found with other clinicopathological parameters (sex, age, size, grading [Edmondson] [33], tumor stage, node stage, etiology), although a trend of increased Gal-1 expression in HCC with vascular invasion was observed (odds ratio = 1.97; 95% confidence interval, 0.97-4.01; P = 0.06) ( Table 7) .
Gal-1 Contributes to Cell Migration and Invasion
The LGALS1 gene expression in JHH-6 cells was significantly increased compared with HuH-7 cells (P = 0.004) (Figure 4A ). In line with LGALS1 gene expression, Gal-1 was expressed at a very high level in JHH-6 cells, whereas it was not detectable in HuH-7 cells ( Figure 4B ). To evaluate the contribution of Gal-1 to aggressiveness of HCC cells, the cDNA of LGALS1 was amplified from JHH-6 total RNA and cloned in a pcDNA3.1 expression vector. HuH-7 cells transfected with the plasmid containing LGALS1 cDNA showed a significant increase of LGALS1 gene expression compared with cells transfected with empty vector ( Figure 4C ). In line with the increased LGALS1 expression in the transfected cells, Gal-1 expression was significantly increased in HuH-7 cells transfected with the plasmid containing LGALS1 cDNA compared with cells transfected with empty vector (Figure 4D) . To determine the effect of Gal-1 on HuH-7 cell migration and invasion, in vitro cell migration and invasion assays were performed. The expression of Gal-1 strongly increased both the migration ( Figure 4E ) and invasion ( Figure 4F ) ability of HuH-7 cells transfected with the plasmid containing LGALS1 cDNA compared with HuH-7 cells transfected with empty vector. In summary, this result showed that Gal-1 was positively associated with the invasiveness of HuH-7 cells.
Gal-1 Induces Syk Phosphorylation in HuH-7 Transfected Cells
To verify the activation of the Syk signaling pathway by Gal-1, we performed immunoblotting analysis on total protein extracts from HuH-7 cells transfected with empty vector and with the plasmid containing LGALS1 cDNA. HuH-7 cells transfected with the plasmid containing LGALS1 cDNA showed an increased phosphorylation of Syk protein compared with cells transfected with empty vector ( Figure 5 ).
DISCUSSION
HCC is one of the most common and aggressive human malignancies (1) . Al- though much is known about both the cellular changes that lead to HCC and the etiological agents responsible for the majority of HCC, the molecular pathogenesis of this disease is not well understood (5). Moreover, the severity of the disease and its clinical heterogeneity combined with the lack of good diagnostic markers and therapeutic strategies makes the treatment of HCC a major challenge.
This study was designed to acquire further insights into the molecular mechanisms of HCC. Several previous study groups have used microarray technology to explore the molecular mechanisms of HCC to possibly find markers or patterns for early detection and diagnosis and for stage classification and prognosis. A typical application of microarrays in HCC study is to classify patients with different disease status. Such studies include the classification of cancer versus nontumor samples, high versus low histological grade, early versus late stage, favorable versus poor prognosis and HCC patients with HBV versus HCV infection. Gene expression signatures were identified to discriminate HBV-positive HCC from nontumor liver tissues (38) and DNs from HCC in HBV (39) and HCV patients (40) , and to monitor the pathological progression of HCV-induced hepatocarcinogenesis at each stage (cirrhosis, dysplasia, early HCC and advanced HCC) (41) . Molecular profiling of HCCs unraveled molecular subtypes of HCC associated with specific signalingpathway alterations (42, 43) . Moreover tumor-derived gene expression patterns have been associated with patient survival (44) , and gene expression signatures of nontumoral liver tissue adjacent to the tumor have been shown to be associated with survival and late recurrence of HCC (45) and with vascular invasion (46) . Although these results showed promise, they appeared rather inconsistent, possibly owing to differences in experimental platforms and/or the underlying biological heterogeneity of the disease.
Our approach identified an HCC molecular signature of 11 genes. Although EDIL3, LGALS1 and SERPINI1 genes have been previously reported to be overexpressed in HCC (28, 36, 37) , the remaining identified genes in this study have never previously been reported. Several of these genes are involved in important biological processes such as transcription regulation (ZIC2, TRIM16), angiogenesis (EDIL3), cell-cell and cell-substrate interactions (LGALS1) and cell movement (LGALS1, MSN) , and accordingly these genes may play an important role in HCC development and progression. Functional studies are necessary to elucidate the role of these genes in HCC pathogenesis and determine their potential as molecular targets for the development of new HCC therapeutic approaches.
EDIL3 is a member of a family of extracellular matrix proteins with multiple EGF-like repeats. EDIL3 is a minor splicing variant of Del1, for which there is extensive literature on its role in promotion of angiogenesis, via interaction with integrin a(v)b3, and the metastatic process (47, 48) . EDIL3 is induced by angiogenesis-related factors, including VEGF1 (49), a factor known to be produced by HCCs (50) . PSCD3 belongs to the PSCD family, whose members are guanine nucleotideexchange proteins, which serve as regulators of ADP ribosylation factors involved in vesicular trafficking and cytoskeletal regulation (51) . Interestingly, the knockdown of PSCD3 mRNA determined the mitotic arrest of the cell cycle (52) . ZIC2 belongs to the ZIC gene family of zinc-finger transcription factors, which are essential for a wide array of developmental programs, including the central nervous system, muscle and skeletal development and the establishment of leftright asymmetry in the early embryo (53) . Human mutations in ZIC family members determine many clinically significant congenital abnormalities (54) . Moreover, aberrant expression of ZIC2 has been observed in medulloblastomas (55) , small cell lung cancers (56), endometrial cancer with node metastasis (57) and in bladder, colon and breast cancer (56) . OGFRL1 encodes the opioid growth factor receptor-like 1, whose biological function is unknown. The opioid growth factor-opioid growth factor receptor interaction plays an inhibitory role in cancerous cell proliferation (58, 59) , cellular renewal in homeostasis, wound healing, development, angiogenesis and cancer (60) . Moesin (membrane-organizing extension spike protein) is a member of the ERM (ezrin-radixin-moesin) protein family. These proteins act as molecular linkers between cell adhesion molecules and the cytoskeleton, regulating cell morphology. These proteins have also been implicated in regulating signaling molecules (61) . In particular, Moesin is localized in the intracellular core of microextensions known as filopodia, microvilli, microspikes, and retraction fibers. This subcellular distribution closely follows the dynamic changes in cell shape that take place when cells attach, spread and move spontaneously, or in response to extracellular signals. Therefore, Moesin could be involved in the dynamic restructuring of such microdomains by regulating binding interactions between the plasma membrane and the actin cytoskeleton (62) . TRIM16 is a member of the RING-B box-coiled-coil protein family; its biological function has not been well characterized. However, evidence seems to suggest that TRIM16 may play a role in the response of tissues to differentiating agents (63) , have a pivotal role in the retinoid anticancer signal (64, 65) and play a role in innate immunity by enhancing the alternative secretion pathway of interleukin 1β (66) . AKR1C3 converts adrenal androgens such as androstenedione and dehydroepiandrosterone into intraprostatic testosterone. AKR1C3 regulates ligand access to steroid hormone and prostaglandin receptors and may stimulate proliferation of prostate and breast cancer cells (67, 68) . Increased expression of AKR1C3 has been shown to strongly correlate with prostatic carcinogenesis (69, 70) , malignant breast lesions (71) and endometrial cancer (72) , indicating AKR1C3 plays a role in prostate, breast and endometrial carcinogenesis. Therefore, AKR1C3 is a potential target in treating prostate, breast and endometrial cancers (73) .
We focused our attention on the LGALS1 gene, which encodes Gal-1 protein. Although differential expression of LGALS1 in human HCC specimens was not the most important one statistically, this gene is the most interesting among those identified because Gal-1 is involved in various aspects of tumorigenesis and has been described as a promising cancer target (11) (12) (13) . The mechanisms related to how Gal-1 contributes to cancer progression and metastasis have been proposed: it regulates tumor cell growth (74), triggers the death of infiltrating T cells (75) , suppresses T-cell-derived proinflammatory cytokine secretion (76) , mediates cell-cell or cell-extracellular matrix adhesion (77, 78) , is involved in tumor angiogenesis (79) and promotes cancer cell migration (24, 80) .
We observed the increased expression of LGALS1 in HCC specimens compared with cirrhotic tissues. Furthermore, we observed preferential accumulation of Gal-1 in the delicate stromal tissue surrounding neoplastic hepatocytes of HCC tumors. Because Gal-1 protein is secreted and can be found on the extracellular side of all cell membranes as well as in the extracellular matrices of various normal and neoplastic tissues (77, (80) (81) (82) (83) (84) (85) , we hypothesize that the significant decrease of Gal-1 expression in the hepatocytes of HCC and its significant corresponding increase in the stromal tissue surrounding neoplastic hepatocytes of HCC could be due to the increased secretion of Gal-1 by neoplastic hepatocytes and its accumulation in the stroma surrounding HCC. In support of our hypothesis, an increased secretion of Gal-1 in conditioned medium pression changes or gene mutations in tumor cells or carcinoma-associated stromal cells increase their malignancy and accelerate cancer progression. Several chromosomal aberrations and genes were positively related to HCC invasion and metastasis (91, 92) . Our data provide evidence that Gal-1 also affects the invasive ability of HCC cells. Therefore, further studies should be conducted both to fully unravel the role of Gal-1 in HCC pathogenesis and to evaluate Gal-1 as a molecular therapeutic target for HCC.
In conclusion, this study provides a portfolio of targets useful for future investigations into molecular-marker discovery studies on many patients and functional assays. These further studies could lead to the identification of markers that can be used to predict diagnosis and prognosis of HCC, may provide further insight into the mechanisms of pathogenesis and could also highlight new potential therapeutic targets for patients with this disease. M Capasso is a fellow of Fondazione Italiana per la Ricerca sul Cancro, FIRC. We thank the Array Facility at BIOGEM Institute for the array hybridization. This study was approved by the Ethics Committee of the University "Federico II" of Naples. All participants of this study signed an informed consent form.
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